Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo patch Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Erlotinib Prevention of Oral Cancer (EPOC)

NCT00402779
View directory record Official record
Conditions
Oral Cancer
Interventions
Erlotinib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)

NCT01055886
View directory record Official record
Conditions
Smoking Cessation
Interventions
nicotine patch, placebo patch
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 19, 2026, 7:07 PM EDT
Terminated Phase 3 Interventional

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

NCT00032084
View directory record Official record
Conditions
Lung Cancer
Interventions
smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care
Behavioral · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
175
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723
View directory record Official record
Conditions
Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions
Placebo Aprepitant, Active Aprepitant
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Not applicable Interventional

Lidocaine Patch for Neck Pain

NCT04378959
View directory record Official record
Conditions
Neck Pain, Neck Pain, Posterior
Interventions
Lidocaine patch, Placebo patch
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KEEPS Mammographic Density And Breast Health Ancillary Study

NCT02524561
View directory record Official record
Conditions
Mammographic Density, Abnormal Mammogram
Interventions
CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 19, 2026, 7:07 PM EDT
Terminated Phase 2 Interventional

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

NCT00278824
View directory record Official record
Conditions
Pain
Interventions
Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 4 Interventional

Synera™ for Epidural Needle Insertion

NCT00564785
View directory record Official record
Conditions
Pain Associated With Epidural Needle Insertion
Interventions
Synera(TM), Placebo patch
Drug · Other
Lead sponsor
IWK Health Centre
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional

Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00352625
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%
Drug
Lead sponsor
Alkemira SA
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

PeriOperative ISchemic Evaluation-2 Trial

NCT01082874
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Active Clonidine, Placebo Clonidine, Active ASA, Placebo ASA
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
45 Years and older
Enrollment
10,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function

NCT01314443
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Nicotine Replacement Therapy (NRT), Gamma-Tocopherol, Placebo, Smoking cessation
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

NCT02448381
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
SGX301 (synthetic hypericin), Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UW Quitting Using Intensive Treatment Study (QUITS)

NCT03176784
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Nicotine patch, Placebo Patch, Placebo Pill
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 19, 2026, 7:07 PM EDT
Recruiting Phase 2 Interventional

Study of ALTO-101 in Patients With Schizophrenia

NCT06502964
View directory record Official record
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

NCT01670526
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Impairment
Interventions
Rivastigmine Transdermal Patch
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
8
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 19, 2026, 7:07 PM EDT
Active, not recruiting Phase 2 Interventional

Daily Topical Rapamycin for Vitiligo

NCT05342519
View directory record Official record
Conditions
Vitiligo
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 2Phase 3 Interventional

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 19, 2026, 7:07 PM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 2 Interventional

Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis

NCT00794976
View directory record Official record
Conditions
Lateral Epicondylitis, (Tennis Elbow)
Interventions
Dexamethasone Iontophoretic Patch (low dose), Dexamethasone Iontophoretic Patch (high dose), Dexamethasone Passive Patch, Placebo Patch
Drug
Lead sponsor
Travanti Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

NCT00506285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System (MTS), placebo patch
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 19, 2026, 7:07 PM EDT
Completed Phase 2 Interventional

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00064142
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 19, 2026, 7:07 PM EDT